Ohki Healthcare Holdings Co Ltd

Ohki Healthcare Holdings maintains a market price of 1,341 JPY per share, with a market capitalization of 18.29 billion JPY. The company's price-to-earnings ratio is 6.93, and its price-to-book ratio is 0.59, indicating a relatively low valuation compared to book value. The enterprise value to EBITDA ratio is 11.45, and the enterprise value to revenue ratio is 0.08, suggesting a low valuation relative to revenue. The company's profitability is modest, with a return on equity of 8.52% and a return on assets of 1.89%. These figures are below the typical benchmarks for the pharmaceutical industry, indicating that the company is not generating strong returns relative to its equity and asset base. Ohki Healthcare Holdings' revenue is primarily derived from the production and sales of pharmaceutical products, health food, and related consumer goods. The company's geographic exposure is concentrated in Japan, and there is no indication of significant international diversification in the provided data. The company's growth trajectory is not clearly defined in the provided data. The outlook for the current fiscal year does not include specific numeric deltas for revenue growth. However, the company's operating cash flow is negative at -9.18 billion JPY, and its free cash flow is also negative at -27.5 million JPY, indicating potential liquidity constraints. The risk assessment for Ohki Healthcare Holdings indicates a medium level of liquidity risk and a low level of dilution risk. The company's net cash position is negative after subtracting total debt, which could pose a challenge for maintaining liquidity. The debt-to-equity ratio is 0.46, and the current ratio is 1.14, suggesting that the company has a moderate level of leverage and a relatively stable short-term liquidity position. Recent financial filings and transcripts do not provide specific details on recent events that could significantly impact the company's operations or financial performance. The company's capital expenditure for the latest period is -2.98 billion JPY, indicating a reduction in capital spending.